Galderma Raises 2026 Sales Forecast After Strong Growth
The skincare company projects higher annual growth following a surge in demand for dermatological products.
Updated on Oct. 26, 2026 in Beauty
Live Poll
Do you trust that rising corporate profits in the beauty sector reflect healthy market growth?
Galderma reported a 25.1% increase in net sales to US$4.77 billion during the first nine months of 2026. Following this performance, the firm raised its full-year sales growth forecast to a range of 22.5-23.5%.
Why it matters
The upward revision reflects sustained global demand for injectable aesthetics, dermatological skincare, and therapeutic dermatology products like Nemluvio. Strong third-quarter momentum of 26% growth has bolstered investor confidence in the company's annual outlook.
Therapeutic dermatology sales saw the highest growth at 64.4%, while injectable aesthetics and dermatological skincare rose 13.2% and 16.2%, respectively. The company updated its full-year 2026 sales growth target from an earlier 19-21% range.
The players
Galderma
This Switzerland-based pharmaceutical company specializes in dermatological treatments, injectable aesthetics, and skincare products.
The details
Galderma attributes its financial performance to robust demand across its primary divisions. The Swiss-based company continues to see significant traction for its therapeutic line, particularly with the rollout of products like Nemluvio.
Timeline
Net sales reached US$4.77 billion during the first nine months of 2026.
Sales growth for the third quarter of 2026 hit 26%.
Full-year 2026 sales growth is now projected to be 22.5-23.5%.
Culture Shift
Galderma's performance aligns with the aesthetic medicine market growth report that documents a sustained transition toward non-invasive cosmetic treatments. This reflects a broader societal shift where medical-grade skincare and injectables are increasingly integrated into routine personal wellness.
The company's expansion suggests that patients will likely see wider availability of therapeutic and aesthetic products in local dermatology clinics. Consumers can expect continued innovation in treatment options as high demand fuels ongoing research and development.
The takeaway
Galderma's strong performance highlights the rising influence of medical-grade treatments in the global skincare landscape. Readers may see more providers offering specialized injectable and therapeutic options as the company scales its distribution.
Further reading
Learn more about the latest industry trends in Beauty.
Source note: This article includes information reported by Global Cosmetics News.
Live Poll
Do you trust that rising corporate profits in the beauty sector reflect healthy market growth?
